Literature DB >> 8698351

Revised transthyretin Ile 122 allele frequency in African-Americans.

D R Jacobson1, R Pastore, S Pool, S Malendowicz, I Kane, A Shivji, S H Embury, S K Ballas, J N Buxbaum.   

Abstract

The transthyretin (TTR) Ile 122 variant is associated with cardiac amyloidosis in individuals of African descent. To determine the prevalence of the allele encoding TTR Ile 122 in African-Americans, we have used PCR and restriction analysis to test DNA from African-Americans from various geographic areas, and found an allele frequency of 66/3376 (0.020), which is higher than the value we previously reported in a much smaller pilot study. Our data indicate that this TTR variant is present at equal frequency in African-Americans throughout the U.S., and suggest that this mutation may be a common, often unrecognized cause of cardiac disease in African-Americans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698351     DOI: 10.1007/s004390050199

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  25 in total

Review 1.  Amyloidosis.

Authors:  M F Khan; R H Falk
Journal:  Postgrad Med J       Date:  2001-11       Impact factor: 2.401

2.  Drop-in, drop-out allele-specific PCR: a highly sensitive, single-tube method.

Authors:  Alice Alexander; Nivedita Subramanian; Joel N Buxbaum; Daniel R Jacobson
Journal:  Mol Biotechnol       Date:  2004-11       Impact factor: 2.695

Review 3.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

4.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 5.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

6.  Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.

Authors:  Lei Zhao; Joel N Buxbaum; Natàlia Reixach
Journal:  Biochemistry       Date:  2013-03-04       Impact factor: 3.162

Review 7.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Sabahat Bokhari; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Martha Grogan; Arnt V Kristen; Isabelle Lousada; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Ronald Witteles; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2019-09-04       Impact factor: 8.790

Review 8.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

9.  National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy.

Authors:  Serge C Harb; Muhammad Haq; Kathleen Flood; Angela Guerrieri; Wendy Passerell; Wael A Jaber; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2016-03-25       Impact factor: 5.952

10.  Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.

Authors:  Raymond C Givens; Chris Russo; Philip Green; Mathew S Maurer
Journal:  Aging health       Date:  2013-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.